Yet again, Congress is considering harmful drug pricing policies with complete disregard for the negative impact they will have on patients and our economy. At the same time, they are continuing to enable insurers and pharmacy benefit managers (PBMs) to take advantage of the system by shifting more and more out-of-pocket costs to patients. Instead of addressing a broken insurance system, the most recent proposal doubles down on sweeping government price-setting policies that will threaten patient access to future medicines and innovations.
